Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2019 ASCO Annual Meeting!


Session: Lung Cancer—Non-Small Cell Metastatic

Type: Poster Session

Time: Sunday June 2, 8:00 AM to 11:00 AM

Location: Hall A

Impact of HER2 aberrations on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS STUDY subset analysis.

Sub-category:
Metastatic Non-Small Cell Lung Cancer

Category:
Lung Cancer—Non-Small Cell Metastatic

Meeting:
2019 ASCO Annual Meeting

Abstract No:
9056

Poster Board Number:
Poster Session (Board #379)

Citation:
J Clin Oncol 37, 2019 (suppl; abstr 9056)

Author(s): Hiroe Kayatani, Keisuke Aoe, Kadoaki Ohashi, Hiroshige Yoshioka, Akihiro Bessho, Nobuhisa Ishikawa, Masahiro Yamasaki, Toshiyuki Kozuki, Nobukazu Fujimoto, Yutaka Ueda, Syuuji Bandoh, Isao Murakami, Hirohisa Ichikawa, Tetsuya Kubota, Keisuke Sugimoto, Nagio Takigawa, Takashi Sumikawa, Katsuyuki Kiura; Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan; National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Japan; Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan; Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata, Japan; Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan; Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan; Hiroshima Red Cross and Atomic-Bomb Survivors Hospital, Hiroshima, Japan; Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan; Department of Respiratory Medicine, Kagawa Prefectural Central Hospital, Takamatsu, Japan; Faculty of Medicine, Kagawa University, Kitagun, Japan; National Hospital Organization Higashihiroshima Medical Center, Higashi-Hiroshima, Japan; Department of Respiratory Medicine, KKR Takamatsu Hospital, Takamatsu, Japan; Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Kochi, Japan; Department of Respiratory Medicine, Kobe Red Cross Hospital, Kobe, Japan; Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan; Tottori Prefectural Central Hospital, Tottori, Japan; Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan

Abstract Disclosures

Abstract:

Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a key treatment for EGFR-mutated non-small-cell lung carcinoma (NSCLC). To date, a biomarker to predict whether NSCLC will exhibit a short- or long-term response to first- or second-generation EGFR-TKIs has not been established for clinical use. Human epidermal growth factor receptor-2 (HER2) aberrations are mechanisms for acquired resistance to EGFR-TKIs; however, their impact on EGFR-TKI therapy outcomes in EGFR-mutant NSCLC has not yet been systematically evaluated. Methods: Patients with advanced NSCLC were prospectively registered from more than 35 institutes (HER2-CS STUDY UMIN 000017003). EGFR mutations or anaplastic lymphoma kinase gene translocations were assessed at each institution using a commercially approved test. HER2 protein expression levels were determined by immunohistochemistry (IHC) using the Ventana I-VIEW PATHWAY anti-HER-2/neu (4B5). The IHC status scoring system applied to gastric cancer was used. Results: Of 1,126 screened patients with NSCLC, 354 (31.8%) had EGFR-mutated tumors, and the HER2 protein statuses were as follows: IHC0 (n = 71, 26%), IHC1+ (n = 148, 53%), IHC2+ (n = 51, 18%), and IHC3+ (n = 7, 3%). The patients’ demographics were almost identical in those with lung tumors harboring EGFR mutations and HER2-IHC2+/3+ (group P) or EGFR mutations and HER2-IHC0/1 (group N). The EGFR-TKI response rates were not different between these groups (Table). However, group P showed significantly shorter time to EGFR-TKI treatment failure than group N (median 19.1 vs. 13.3 months; log rank p = 0.038). Conclusions: These data from a large prospective cohort show that HER2 protein expression in EGFR-mutant NSCLC may have a negative impact on the effect of EGFR-TKIs. A clinical trial of EGFR/HER2-TKIs (e.g., afatinib) is warranted for this population.

Group N
Group P
IHC 0
(n = 71)
IHC 1+
(n = 148)
IHC 2+
(n = 51)
IHC 3+
(n = 7)
Complete Response4610
Partial Response4583334
Stable Disease836102
Progressive Disease3951
Not Evaluated41420
Overall response rate69%60%67%57%
Disease control rate80%84%86%86%
Time to treatment failure (months)19.113.1

 
Other Abstracts in this Sub-Category:

 

1. Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.

Meeting: 2019 ASCO Annual Meeting Abstract No: 102 First Author: Ferdinandos Skoulidis
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

2. Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).

Meeting: 2019 ASCO Annual Meeting Abstract No: 110 First Author: Sean Khozin
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

3. RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

Meeting: 2019 ASCO Annual Meeting Abstract No: 9000 First Author: Kazuhiko Nakagawa
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

More...